Osteoporosis Management

2021 ◽  
Author(s):  
Tiffany Cochran ◽  
Tara K. Iyer ◽  
Pelin Batur
Keyword(s):  
Osteoporosis Management

Haemophilia and Osteoporosis Management in Germany

2019 ◽  
Author(s):  
G. Goldmann ◽  
T. Wallny ◽  
P. Müllejans ◽  
U. Daub ◽  
N. Marquardt
Keyword(s):  
Osteoporosis Management

Osteoporosis management in 2017: still thin and fragmented

2017 ◽  
Vol 47 (11) ◽  
pp. 1329-1330
Author(s):  
Angela Sheu ◽  
Lorena Beatriz Ataide Lopes ◽  
John Eisman ◽  
Jacqueline R. Center
Keyword(s):  
Osteoporosis Management

scholarly journals Controversies in Osteoporosis Management

2013 ◽  
Vol 56 (4) ◽  
pp. 749-756 ◽  
Author(s):  
J. CHRISTOPHER GALLAGHER ◽  
SRI HARSHA TELLA
Keyword(s):  
Osteoporosis Management

scholarly journals Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management

2009 ◽  
Vol 84 (7) ◽  
pp. 632-638 ◽  
Author(s):  
Kurt A. Kennel ◽  
Matthew T. Drake
Keyword(s):  
Adverse Effects ◽  
Osteoporosis Management

Propensity of gynaecologists towards osteoporosis management and treatment

Maturitas ◽  
2006 ◽  
Vol 53 (4) ◽  
pp. 483-488 ◽  
Author(s):  
Serge Rozenberg ◽  
Daniel Murillo ◽  
Rudy Gevers ◽  
Jean Vandromme
Keyword(s):  
Osteoporosis Management

scholarly journals The Bromodomain Inhibitor N-Methyl pyrrolidone Prevents Osteoporosis and BMP-Triggered Sclerostin Expression in Osteocytes

2018 ◽  
Vol 19 (11) ◽  
pp. 3332 ◽  
Author(s):  
Barbara Siegenthaler ◽  
Chafik Ghayor ◽  
Bebeka Gjoksi-Cosandey ◽  
Nisarat Ruangsawasdi ◽  
Franz Weber
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Osteoporosis Treatment ◽  
Estrogen Deficiency ◽  
Bone Morphogenetic Protein 2 ◽  
Protein Levels ◽  
Osteoporosis Management ◽  
Promising Target

(1) Background: In an adult skeleton, bone is constantly renewed in a cycle of bone resorption, followed by bone formation. This coupling process, called bone remodeling, adjusts the quality and quantity of bone to the local needs. It is generally accepted that osteoporosis develops when bone resorption surpasses bone formation. Osteoclasts and osteoblasts, bone resorbing and bone forming cells respectively, are the major target in osteoporosis treatment. Inside bone and forming a complex network, the third and most abundant cells, the osteocytes, have long remained a mystery. Osteocytes are responsible for mechano-sensation and -transduction. Increased expression of the osteocyte-derived bone inhibitor sclerostin has been linked to estrogen deficiency-induced osteoporosis and is therefore a promising target for osteoporosis management. (2) Methods: Recently we showed in vitro and in vivo that NMP (N-Methyl-2-pyrrolidone) is a bioactive drug enhancing the BMP-2 (Bone Morphogenetic Protein 2) induced effect on bone formation while blocking bone resorption. Here we tested the effect of NMP on the expression of osteocyte-derived sclerostin. (3) Results: We found that NMP significantly decreased sclerostin mRNA and protein levels. In an animal model of osteoporosis, NMP prevented the estrogen deficiency-induced increased expression of sclerostin. (4) Conclusions: These results support the potential of NMP as a novel therapeutic compound for osteoporosis management, since it preserves bone by a direct interference with osteoblasts and osteoclasts and an indirect one via a decrease in sclerostin expression by osteocytes.

scholarly journals Evaluation of a Nationwide Pharmacist-Led Phone Outreach Program to Improve Osteoporosis Management in Older Women with Recently Sustained Fractures

2015 ◽  
Vol 21 (9) ◽  
pp. 803-810 ◽  
Author(s):  
Luke S. Tso ◽  
Danmy Loi ◽  
David G. Mosley ◽  
David Yi ◽  
Karen M. Stockl ◽  
...  
Keyword(s):  
Older Women ◽  
Outreach Program ◽  
Osteoporosis Management

How to assess osteoporosis management efficacy?

2010 ◽  
Vol 75 (6) ◽  
pp. 681-682 ◽  
Author(s):  
W. Pluskiewicz ◽  
B. Drozdzowska
Keyword(s):  
Osteoporosis Management
Sign in / Sign up

Export Citation Format

Share Document